Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2001

View Archived Issues

Bayer and CuraGen establish two collaborative agreements

Bioniche's MCC technology approved for prostate cancer clinical trials

Study of RSR-13 in combination with chemotherapy commences

Amylin reports company update and projections

Aphton to commence study of GnRH pharmaccine in combination with Taxotere

First once-monthly injectable contraceptive now available in the U.S.

World's first diagnostic agent for Parkinson's disease reaches market in Europe

Aventis Pasteur launches Hexavac, a significant advance in childhood vaccination

Worldwide licensing arrangement announced for TZT-1027

YM-905 enters late-stage clinical development overseas

Novogen receives grant for development of antiinflammatory drug

Traditional Chinese medicine has beneficial effects on body fat and triglycerides in animal model

Ligand's Ontak enters phase II for CLL

Halofuginone affects critical steps in the angiogenic process

Patient enrollment in OCTAVE hypertension trial nears completion

Phase II trials of ADL-8-2698 in opioid-induced bowel dysfunction successfully completed

Allergan obtains rights to compound for PDT of age-related macular degeneration

Combinations of lipopeptides and other antifungal agents reported to be synergistic

Neurochem cleared to advance Fibrillex to phase II/III clinical trials in the U.K.

Novel combination therapies useful for weight gain associated with antipsychotic drugs

Use of rhIL-11 for the treatment of hemorrhagic shock described by Genetics Institute

New series of 5-HT7 antagonists designed by the former SB

Inhibitors of NOS and their therapeutic use claimed in recent patents by AstraZeneca

Clinical evaluation of FKK-138 following single bolus doses

Antitumor compounds active against solid tumors and leukemias in the ADIR pipeline

Japanese team discloses new aldose reductase inhibitors

Quinazoline ACAT inhibitors and their use in lipid disorders

Antifungal antibiotic isolated from Penicillium sp. at Takara Shuzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...